2025-02-02 - Analysis Report
## Merck & Co Inc (MRK) Stock Review

**0. Key Figures Summary:**

* **Cumulative Return (MRK):** 63.14%
* **Cumulative Return (VOO):** 119.91%
* **Return Difference (MRK vs VOO):** -56.8%  (Relative Divergence: 6.7%)
* **Current Price:** $98.82
* **RSI:** 48.63
* **PPO:** 0.13
* **Expected Return (vs. S&P 500, long-term):** 95.9%


**1. Performance Comparison & Company Overview:**

Merck & Co Inc (MRK) is a leading pharmaceutical company.  Over the analyzed period, MRK significantly underperformed the S&P 500 (VOO), exhibiting a cumulative return of 63.14% compared to VOO's 119.91%. This represents a -56.8% difference. The relative divergence of 6.7% indicates that the current underperformance is relatively low compared to the historical range of underperformance observed between the two assets.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | -2.0% | 11.8% | -0.3 | 1.1 |
| 2016-2018  | 46.0% | 11.8% | 0.5 | 1.5 |
| 2017-2019  | 44.0% | 11.8% | 0.3 | 1.9 |
| 2018-2020  | 32.0% | 9.4% | 0.2 | 1.7 |
| 2019-2021  | 3.0% | 14.3% | 0.2 | 1.8 |
| 2020-2022  | 47.0% | 14.3% | 0.2 | 2.7 |
| 2021-2023  | 55.0% | 14.3% | 0.3 | 2.7 |
| 2022-2024  | 21.0% | 9.5% | 0.3 | 2.5 |
| 2023-2025  | -23.0% | 9.5% | 0.2 | 2.5 |

**Analysis of Alpha and Beta:**  The alpha values fluctuate around 0, indicating that MRK's returns have largely been explained by market movements (beta).  High beta values suggest significant market sensitivity.  The volatile CAGR reflects periods of strong performance alongside periods of underperformance.  The MDD (Maximum Drawdown) also shows periods of substantial losses.


**2. Recent Price Movement:**

* **Closing Price:** $98.82
* **5-Day Moving Average:** $98.29
* **20-Day Moving Average:** $98.65
* **60-Day Moving Average:** $99.31

The price is slightly below all three moving averages, suggesting a mild short-term downtrend.  The small negative change (-0.13) from the previous close doesn't indicate a significant price movement (not a sharp drop or surge).


**3. Technical Indicators & Expected Return:**

* **RSI (48.63):**  Near the neutral level (50), suggesting neither overbought nor oversold conditions.
* **PPO (0.13):**  Slightly positive, indicating a potential bullish momentum.
* **Relative Divergence (20-day):** +6.7% suggests a short-term upward trend compared to the S&P 500.
* **Expected Return (Long-term):**  95.9% indicates a substantial outperformance potential relative to the S&P 500 over the long term (2+ years).


**4. Recent Earnings Analysis:**

| 날짜       | EPS    | 매출           |
|------------|--------|-----------------|
| 2024-11-06 | 1.25   | $16.66B         |
| 2024-08-05 | 2.15   | $16.11B         |
| 2024-05-03 | 1.88   | $15.78B         |
| 2023-11-03 | 1.87   | $15.96B         |
| 2024-11-06 | 1.87   | $15.96B         |

There appears to be a duplicate entry for 2024-11-06.  EPS and Revenue fluctuate somewhat, but a detailed analysis requires further data and context (e.g., comparison to previous years, industry benchmarks).  The November 2024 data points to a significant drop in EPS compared to the August figure.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter     | Revenue    | Profit Margin |
|-------------|------------|---------------|
| 2024-09-30 | $16.66B    | 75.51%        |
| 2024-06-30 | $16.11B    | 76.76%        |
| 2024-03-31 | $15.78B    | 77.56%        |
| 2023-12-31 | $14.63B    | 73.26%        |
| 2023-09-30 | $15.96B    | 73.29%        |

Revenue shows a generally increasing trend. Profit margins are high and relatively stable, although there's some fluctuation.

**Capital and Profitability:**

| Quarter     | Equity      | ROE           |
|-------------|-------------|---------------|
| 2024-09-30 | $44.50B     | 7.09%         |
| 2024-06-30 | $43.58B     | 12.52%        |
| 2024-03-31 | $40.36B     | 11.80%        |
| 2023-12-31 | $37.58B     | -3.26%        |
| 2023-09-30 | $41.25B     | 11.50%        |

Equity is generally increasing. ROE fluctuates considerably, with a negative value in Q4 2023. This needs further investigation to understand the underlying causes.


**6. Overall Analysis:**

MRK has shown significant underperformance compared to the S&P 500 in the past, although recent short-term trends might be more positive.  While the long-term expected return is high, this projection must be viewed cautiously.  The company shows high profit margins and generally increasing revenue. However, inconsistent earnings and fluctuating ROE raise concerns.  A more thorough analysis, including consideration of external factors (market conditions, competitive landscape, regulatory changes) and a deeper dive into the causes of earnings and ROE volatility is necessary before drawing definitive conclusions about MRK's investment potential.  The provided data suggests a mixed picture, highlighting both strengths and weaknesses.
